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Anne Claire Desbois1,2*, Pierre Emmanuel Rautou3, Lucie Biard5, Nadia Belmatoug4, Bertrand Wechsler1,
Mathieu Resche-Rigon5, Virginie Zarrouk4, Bruno Fantin4, M Pineton de Chambrun1, Patrice Cacoub1,2,6,
Dominique Valla3, David Saadoun1,2,6 and Aurélie Plessier3Abstract
Background: Behcet’s disease (BD) is a well-known cause of Budd-Chiari syndrome (BCS). Data are lacking on the
presentation and outcome of BCS related to BD.
Methods: We investigated the relationship between BD and BCS in 14 patients with both diseases and compared
the results to 92 BCS patients without BD.
Results: Male gender (p = 0.003), North African origin (P = 0.007) and inferior vena cava obstruction (P < 0.0001) were
more frequent in patients with BD and BCS than in those with BCS alone and the plasma C-reactive protein level was
higher (p = 0.003). Two of the patients with the combined diseases underwent recanalization of the vena cava and the
hepatic veins, none received transjugular intrahepatic portosystemic shunts (TIPS), one received a surgical shunt and
one underwent liver transplantation. TIPS were less frequent in patients with BD and BCS than in those with BCS alone
(P = 0.019). Eighty six per cent of patients with BCS and BD received corticosteroids and immunosuppressive therapy.
The 5-year transplantation-free survival rate was 63% in patients with BCS alone and 91% in those without BD (P = 0.11).
In our series and in the literature, a high number of patients [12 (61.5%) and 11 (64.7%) respectively] treated with
anticoagulation and corticosteroids and/or immunosuppressants did not require invasive treatment.
Conclusion: This study shows a higher frequency of IVC obstruction in patients with BCS and BD. Medical
treatment with anticoagulation and immunosuppressive agents may improve the symptoms of BCS. Therefore
early management with immunosuppressive and anticoagulation therapy appears to be the treatment of choice
in patients with BCS and BD.
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Budd Chiari Syndrome (BCS) is related to an obstruc-
tion of the hepatic venous outflow tract at the hepatic
veins or the inferior vena cava (IVC). This condition is
associated with a high risk of complications and death
due to portal hypertension and liver failure. Most cases
of BCS are related to thrombosis resulting from one or
several prothrombotic conditions [1]. Myeloproliferative
disorders are associated in approximately 50% of cases,
and represent the leading cause of primary BCS. Other* Correspondence: anneclairedesbois@yahoo.fr
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unless otherwise stated.acquired [e.g. antiphospholipid syndrome (about 10%) or
paroxysmal nocturnal hemoglobinuria (about 2%)] and
inherited conditions are the cause in a smaller proportion
of BCS. Behcet’s disease (BD) is found in approximately
5% of patients with BCS in western countries [1]. BD was
reported in 9% of BCS patients in Turkey, making it the
third cause of the disease in that country [2], and 13% of
patients in Egypt [3].
BD is a chronic and relapsing vasculitis characterized by
oral and genital aphtosis, ocular inflammation as well as
cutaneous, vascular and nervous system manifestations
[4]. Vasculitis is the main pathological finding of BD, and
all sized vessels can be involved in the arterial and venous
systems [5-7], although venous involvement is more fre-
quent than arterial. In a recent survey, 37% of BD patients
had venous thrombosis, and BCS occurred in 2.4% of these
cases [8]. BCS is the most severe venous manifestation of. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0) which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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these patients [8].
Because BD and BCS are uncommon, data on BCS re-
lated to BD are limited to small retrospective series or
single case reports. Thus data on the clinical features
and the outcome and management of patients with BCS
and BD are lacking. The present study retrospectively
compared 14 patients with both diseases to 92 patients
with BCS without BD.
Methods
Patients
The characteristics of 14 consecutive BCS patients with
BD diagnosed between 1995 and 2012 were compared to
those of a previously reported cohort of 92 BCS patients
without BD, diagnosed between 1995 and 2005 [9]. All
fourteen patients with BCS and BD met the ICBD cri-
teria for BD [4]. BD patients were followed in both de-
partments [the department of internal medicine at
Hôpital Pitié-Salpêtrière (Paris, France) and the liver unit
at Hôpital Beaujon (Clichy, France) for BCS manage-
ment]. The patients with BCS without BD were followed
at the Hepatology Department of the Hôpital Beaujon.
The diagnosis of BCS was based on confirmation of hep-
atic venous outflow tract obstruction based on imaging
data: venous Doppler ultrasound, CT angiography and/
or magnetic resonance angiography (MRA).
Venous outflow obstruction due to right-sided heart
failure and sinusoidal obstruction syndrome were not
included.
Data on demographic characteristics were collected dur-
ing the study period (gender, age and geographic origin),
clinical presentation of BCS (date of BCS, main symptoms,
number of occluded veins), risk factors for thrombosis
[proteins C, S and antithrombin III deficiency R506Q mu-
tation of factor V, G20210A mutation of prothrombin and
C677T mutation of methylene-tetrahydrofolate-reductase
(MTHFR) gene, plasma homocysteine level, anticardiolipin
and anti-β2Gp1 antibodies, tests for paroxysmal nocturnal
hemoglobinuria and JAK2 V617F mutation] and labora-
tory findings (liver enzymes, serum creatinine, prothrom-
bin time) and imaging features. Search for signs of BD
were recommended as part of the routine work-up. Treat-
ment and overall survival was recorded for each patient.
The Rotterdam prognostic score was calculated according
to Murad et al. [10].
Statistical analysis
Patient characteristics and survival were compared be-
tween BCS patients with and without BD. Quantitative
variables are reported as medians and ranges and were
compared by the Wilcoxon rank-sum test. Categorical
variables were described with counts and percentages
and were compared by the Fisher’s exact test. Overallsurvival was defined as the time between the date of
diagnosis of BCS and death. Living patients were cen-
sored at the date of the last recorded follow-up visit.
Overall survival was estimated using the Kaplan Meier
estimator and compared between groups by the log rank
test. The probability of survival was presented as a
percent and a 95% confidence interval. All tests were
two-sided and P-values ≤0.05 were considered to be sig-
nificant. Analyses were performed using the R statistical
software version 2.14.0 (available online at http://www.
R-project.org).Review of the literature
We systematically reviewed the medical literature via
PubMed using the following keywords: “Budd-Chiari
Syndrome”, “Behcet’s disease” and “hepatic vein occlu-
sion”. We only analyzed cases reports and series pub-
lished after 1980 in English or in French.Results
Baseline characteristics
Baseline characteristics of the 106 patients with BCS
with and without BD are summarized in Table 1. Four-
teen BCS patients also had BD. The median age at diag-
nosis of BCS was 33 years old (range 22–45) and 79%
were men. Male gender (p = 0.003) and North African
origin (p = 0.007) were more frequent in patients with
BCS and BD than in those without BD (n = 92).
Four (28.6%) patients had already been diagnosed with
BD when BCS was diagnosed [median time 11 months
(range 3–97 months)]. The diagnosis of BD was con-
comitant with the diagnosis of BCS in 8 (57%) patients.
In the remaining 2 patients, BD was diagnosed 14 and
30 months after BCS, respectively. Major organ or tissue
involvement of BD included oral (100%) and genital mu-
cosa (64%), eyes (29%), joints (29%), nervous system
(21%), arterial bed (29%) and heart (50%).
Ascites and splenomegaly were less common in BCS pa-
tients with BD than in those without (Table 1). Median C-
reactive protein (CRP) levels at the diagnosis of BCS were
higher in BD patients than in those without. Laboratory
results were similar in both groups, except for a lower
serum bilirubin level in BD patients. IVC obstruction
(suprahepatic and infrahepatic IVC occlusions) at pres-
entation was almost 4 times more common in BD pa-
tients with BCS than in those without BD. Most (n =11,
79%) patients with BCS and BD had other types of ven-
ous thrombosis as described in Table 2. Most of these
thromboses were diagnosed at the same time as BCS in
BD patients. Five patients (36%) with BCS and BD had
an associated prothrombotic condition (Table 2). Three
out of 14 BD patients [21.4%, 95% CI (7.1; 48.5)] were
HLA B51 positive.
Table 1 Baseline characteristics of BCS patients with and without BD
BCS with BD (n =14) BCS without BD (n =92) p
Age at BCS diagnosis, median (range) 33 (22–45) 38 (16–77) 0.086
Male gender, n (%) 11/14 (79%) 32/92 (35%) 0.003
Geographic origin 0.0002
Europe 6 (43%) 66 (73%)
North Africa 8 (57%) 12 (13%)
Type of outflow obstruction
IVC occlusion, n (%) 10/14 (71%) 16/91 (18%) < 0.0001
HV occlusion alone, n (%) 4/11 (36%) 75/91 (82%) 0.002
Combined HV and IVC occlusion, n (%) 6/11 (55%) 15/91 (16%) 0.009
Number of hepatic veins thrombosed, median ± SD 2 3 0.017
1 HV thrombosed, n (%) 3/10 (30%) 5/91 (5%)
2 HV thrombosed, n (%) 1/10 (10%) 13/91 (14%)
3 HV thrombosed, n (%) 5/10 (50%) 72/91 (79%)
Clinical features at baselinea, n (%)
Ascites 6/13 (46%) 72/92 (78%) 0.036
Hepatomegaly 6/13 (50%) 55/92 (60%) 0.38
Splenomegaly 2/12 (17%) 51/92 (55%) 0.014
Abdominal pain 6/13 (46%) 62/92 (67%) 0.21
Hepatic encephalopathy 0/13 7/90 (8%) 0.59
Gastrointestinal bleeding 0/13 10/92 (11%) 0.36
Laboratory at baselinea
ALT < 5 × ULN, n (%) 10/11 (91%) 60/92 (65%) 0.10
AST < 5 × ULN, n (%) 10/11 (91%) 63/92 (68%) 0.17
Bilirubinemia (μmol/l), med(min-max) 13 (6–38) 31 (7 – 207) < 0.0001
Albuminemia (g/l), med(min-max) 37(26–49) 35(19–52) 0.94
CRP level (mg/L), med(min-max) 85(7–238) 16(3–344) 0.003
Creatinemia (μmol/L), med(min-max) 80(44–120) 73(36–428) 0.34
Prothrombin Time < 70%, n (%) 5/11 (45.5%) 62/92 (67.4) 0.19
Thrombopenia (< 150.10 [9]/L), n (%) 2/12 (16.7%) 18/92 (19.6%) 1
Rotterdam BCS index 1 (0.0;1.2) 1.2 (0.0;3.9) 0.0007
Abbreviations: ALT Alanine aminotransferase, AST Aspartate aminotransferase, BD Behcet’s disease, BCS Budd-Chiari Syndrome, CRP C reactive protein, HV Hepatic
vein, IVC Inferior vena cava, Med Median, ULN Upper limit of normal.
aIn BD patients, laboratory values at baseline were available in 11 patients for AST, ALT, creatinemia and CRP level, in 10 patients for albuminemia and in 12
patients for biliburinemia.
In BCS patients without BD, laboratory values were available in 90 patients for bilirubinemia, in 73 patients for albuminemia, in 87 patients for creatinemia and 41
patients for CRP level.
Bold indicates significant differences.
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The main features of BCS related treatment are indi-
cated in Table 3 and Figure 1. Treatment included
anticoagulation with heparin followed by a coumarine
derivative in all cases. None of the BCS patients with
BD received transjugular intrahepatic portosystemic
shunts (TIPS) and one underwent liver transplantation.
Patients with BCS and BD received TIPS less frequently
and vena cava thrombolysis more often than those
without BD (Table 3). The reason that TIPS were not
used included a good response to medical therapy in 11patients with BCS, or a contraindication due to associ-
ated IVC obstruction in 3.
Complications of anticoagulation included epistaxis
and hematuria in 1 patient.
Treatment of BD
Specific treatment for BD is presented in Figure 1.
Twelve (86%) patients with BCS and BD received corti-
costeroids (0.5-1 mg/kg/day of oral prednisone in 12 pa-
tients including pulses of 1 g methylprednisolone for
3 days in 2 cases). Twelve (86%) patients received
Table 2 Disease characteristics of patients with BD and
BCS
Patients with BD and BCS
(n = 14)
Additional etiologic factors, n (%) 5 (38.5%)
Antiphospholipid antibodies 2
Hyperhomocyteinemia 2
Factor II heterozygous gene mutation 1
Associated venous thrombosis, n (%)
Pulmonary embolism 7 (50%)
Intracardiac [right atrium/right ventricle] 5 (36%) [29%/7%]
Superior vena cava 3 (21%)
Lower limbs 4 (29%)
Cerebral 1 (7%)
Abbreviations: BCS Budd-Chiari Syndrome, BD Behcet’s disease.
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3 mg/kg/day, n = 9), cyclophosphamide (pulses of 750 mg/
m [2] /4 weeks during 6–12 months, n = 4), oral cyclospor-
ine (3 mg/kg/day, n = 1). One patient received anti-tumor
necrosis factor-α (anti-TNFα) inhibitor (infliximab 5 mg/kg
intravenously at week 0, 2, 6 and every 6 to 8 weeks,
n = 1). Three patients received 2 immunosuppressive and/
or biologic agents [cyclophosphamide followed by azathio-
prine (n = 1) or cyclosporine (n = 1) and infliximab
followed by azathioprine (n = 1)].
Two (15.4%) of the 13 patients who received anti-
coagulation and corticosteroids and/or immunosup-
pressants died; immunosuppressive therapy was started
more than 2 years after the diagnosis of BCS in 1 of
these. Eight (61.5%) of these 13 patients did not require
endovascular treatment or surgery. The 5 other patients
required additive invasive treatments [thrombolysis
(n = 3), additional stent (n = 1) and surgical decom-
pression by mesoatrial shunting (n = 1)]. This last pa-
tient was still alive after surgery at the end of follow up
but had refractory ascites.
The patient who received only anticoagulation had a
favourable outcome.Table 3 Main treatments of BCS patients with and without BD
BCS with BD (n =14)
Anticoagulation, n (%) 14 (100%)
Endovascular treatment, n (%) 2 (14%)
Thrombolysis, n (%) 3 (21%)
TIPS, n (%) 0 (0%)
Surgical decompressiona, n (%) 1 (8%)
OLT, n (%) 1 (7%)
Abbreviations: BCS Budd-Chiari Syndrome, BD Behcet’s disease, TIPS Transjugular int
aData on surgical decompression was available for 13 patients in BCS patients with
Bold indicates significant differences.The main complications of immunosuppressive agents
included adenitis with azathioprine (n = 1), zoster infec-
tion with anti-TNF alpha therapy (n = 1) and pancytopenia
under azathioprine (n = 1).Survival
Median follow-up for the study group (n = 106) was
54 months (range 1–142 months). Mortality in BCS pa-
tients with BD was 14.3% after a median follow up of
53 months. One and 5-year overall survival rates were
84% (CI 95% 77–92) and 79% (CI 95% 71–88) respect-
ively in BCS patients without BD; and 100% and 91% (CI
95% 75–100) respectively in BCS patients with BD (no
significant difference) (Figures 2a and b). Transplant-
ation free survival rates in BCS patients with and with-
out BD, were 100% and 77% (CI 95% 68–86) at 1 year,
and 91% (CI 95% 75–100) and 63% (CI 95% 53–75) at
5 years, respectively.
Death was related to liver disease in the 2 patients
with BD who died.Literature review
Out of the 95 BD patients with BCS reported in litera-
ture, the 61 from publications in English and French
were included in the study [11-32]. Data were obtained
from 19 case-reports including fewer than 5 patients)
and 3 series (including more than 5 consecutive pa-
tients). Ninety percent of the patients were men. Median
age was 26 years old (range 12–58). All patients were
symptomatic. Ninety eight percent of the patients had
ascites, 74% hepatomegaly, 26% splenomegaly, 23% ab-
dominal pain, 16% jaundice and 13% hepatic encephal-
opathy. Most patients had elevated liver enzymes. The
mean serum bilirubin level was 79 μmol/L, and the
mean prothrombin time ratio was 49%. Ninety one per-
cent of the patients had associated IVC thrombosis.
Lower limb thrombosis, intracardiac thrombosis, pul-
monary embolism and renal vein thrombosis were asso-
ciated with BCS in 28, 22, 13 and 9% of the patients,
respectively.BCS without BD (n =92) p
92 (100%) 1.00
17 (18%) 1.00
1 (1%) 0.007
28 (30%) 0.019
7 (8%) 1.00
15 (16.3%) 0.69
rahepatic portosystemic shunt, OLT Orthotopic liver transplantation.
BD.
Figure 1 Outcome of the 14 BD patients according to treatments (specific treatments of BD and treatments of BCS).
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tients with BCS and BD reported in literature. Data are
summarized in Table 4. After a mean follow-up of
30 months, 19 (59%) patients improved, 11 (34%) died, 1
relapsed and 1 had persistent ascites. Two (12%) of the
17 patients treated with anticoagulation, corticosteroids
and/or immunosuppressive agents, died (despite surgical
decompression in one), 11 (65%) improved without re-
ceiving endovascular/surgical treatment, 2 improved
after surgical or endovascular treatment, 1 had persistent
ascites and 1 relapsed 5 years after surgery. Four (67%)
of the 6 patients treated with corticosteroids with or
without immunosuppressants and without anticoagula-
tion died and 2 had a favourable outcome. Three of the
5 patients (60%) treated with anticoagulation only died
(despite surgical decompression in one case) and 2 were
still alive in good physical condition after thrombectomy
in one [14]. Two of the 4 patients who did not receive
anticoagulation, corticosteroids or immunosuppressive
agents died (including one after thrombectomy) and theremaining 2 cases improved [after intravenous throm-
bolysis (n = 1) and with aspirin and colchicine (n = 1)]
[11].
Discussion
This study reports the largest series of consecutive pa-
tients with BCS and underlying BD. Most previous stud-
ies of this rare combination of disorders have consisted
of case reports and therefore little is still known about
the specific clinical features, treatment outcome or prog-
nosis. In the current study, we compared the course of
the disease in 14 patients with BCS and BD to a cohort
of patients with BCS in whom BD was excluded as the
underlying cause. Previous surveys indicate that BD may
be responsible for up to 13% of the cases of BCS [1-3].
The results of this study confirm and expand those
from previous smaller studies [3,17] on baseline charac-
teristics of patients at diagnosis of BCS. The main clin-
ical features at diagnosis of BCS that differed between
patients with and without BD were a younger age, a
Figure 2 Overall survival in BCS patients with (n = 14) and without (n = 92) BD (a); Transplantation free survival in BCS patients with
(n = 14) and without (n = 92) BD (b).
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and a higher frequency of associated thrombosis in other
territories, as expected for BD patients in general. These
findings are similar to the data from Bismuth et al. who
reported male predominance (male/female ratio, 19:1) in
BCS patients with BD compared to those without (i.e.
mainly patients with myeloproliferative disorders) [17].
Our study reported a 4-fold higher prevalence of IVC
thrombosis in patients with than in those without BD.
This emphasizes the significant association between BCS
and IVC occlusion in patients with BD. Thus, the pres-
ence of IVC thrombosis in patients with BCS should
suggest BD, which should then be investigated. Indeed,
the diagnosis of BD had not yet been made in 2/3 of
BCS patients with BD when BCS occurred. In our study,
most of patients with BCS and BD had thrombosis in
other territories (i.e. pulmonary artery, intracardiac, su-
perior vena cava) which might be a useful indication to
suggest and search for BD.
Despite a higher frequency of associated IVC throm-
bosis, the short-term prognosis of BCS patients with BD
did not differ from that in BCS patients without BD.
The presence of associated IVC thrombosis in BD pa-
tients and the favourable outcome under immunosup-
pressants explain in part the low frequency of TIPS.
Bayraktar et al. [22] observed a better outcome in BD
patients with BCS without IVC thrombosis (100% sur-
vival in 2 patients) while the mortality was 66% in pa-
tients with BCS and IVC thrombosis (n = 8) . In ourcohort, none of the 4 patients with BCS and BD without
IVC obstruction died. However, in recent surveys on
BCS from all causes, IVC obstruction was not found to
be associated with death or an intervention in multivari-
ate analysis [33-35].
Early diagnosis of BD is necessary in BCS patients to
begin early and specific treatment for BD. Indeed in the
present study and in the literature, pharmacological antic-
oagulation and immunosuppression alone were associated
with favourable outcomes in patients with BCS and BD.
However, it is important to remember that results in the
literature are retrospective and include mainly case-
reports, which may cause a significant reporting bias.
Moreover, differences with our cohort might also be
caused by less uniform management in case-reports. In
our survey, the mortality rate in patients treated with
anticoagulation and corticosteroids and/or immunosup-
pressants was 18%. In the literature, the mortality rate in
patients with similar treatment was 12% but was 60% in
patients treated with anticoagulation only. In our cohort, 8
(62%) patients had a favourable outcome with medical
therapy alone (i.e. anticoagulation and immunosuppressive
agents and/or corticosteroids) and without endovascular
treatment or surgery. In contrast in a large series of
BCS from all causes, only 20-49% of patients treated
with anticoagulation alone without invasive treatment
had a favourable outcome [36,37].
The pathogenesis of thrombosis in BD is not fully
understood. Thus far no consistent primary coagulation
Table 4 Treatments and outcome of the 61 BD patients with BCS reported in literature
Date of
publication/authors
Number of
patients
Anti-
coagulation
Cortico-
steroids
Immuno-
suppressive
therapy
Surgery Endovascular
treatment
Outcome Follow up
(months)
1980/ [11] 1 0 0 0 0 0 death 4
1996/ [20] 1 0 0 0 1(thrombectomy) 0 death During
surgery
2000/ [23] 1 0 0 0 0 0 favourable 180
1983/ [13] 1 T 0 0 0 0 favourable 72
No treatment 4 0 (T, n =1) 0 0 1 thrombectomy 0 Death n = 2 (50%)
1985/ [14] 1 0 1 1 0 0 favourable 24
2002/ [24] 1 0 1 1 0 0 death 3
2007/ [28] 1 0 1 0 0 thrombolysis
(failure)
death ND
2007/ [29] 3 0 3 3 0 0 death (n = 2)
favourable (n = 1)
7;7;6
No ATCG 6 0 6 5 0 0 Death n = 4 (67%)
1983/ [12] 1 1 0 0 1(shunt) 0 death 1
1986/ [15] 1 1 0 0 0 1 (stent) favourable 36
1991/ [18] 1 1 0 0 0 0 death 1.25
1990/ [17] 1 1 0 0 0 0 favourable 24
2008/ [30] 1 1 0 0 0 0 death ND
ATCG alone 5 5 0 0 1 1 Death n = 3 (60%)
1990/ [17] 3 3 (T, n = 1) 2 1 2 (shunt) 0 death (n = 1) 30;4;4
2002/ [25] 1 1 1 0 1 0 relapse (n = 1) 60
2004/ [26] 1 1 1 1 0 dilatation
and stent
favourable 0.25
2007/ [27] 4 4 4 4 0 0 death (n = 1) 1;96;48;36
2008/ [30] 6 6 6 2 0 0 favourable (n = 6) 43
2011/ [31] 1 1 1 1 0 0 favourable 1
2011/ [32] 1 1 1 1 0 0 alive 1.5
ATCG and IS 17 17 16 10 3 1 Death n = 2 (12%)
TOTAL 32 ATC 22 (69%) 22 (69%) 15 (47%) 5 (16%) 3 (9%) 12 (38%) 29.7 months
Thrombolysis
2 (6%)
Abbreviations: ATC Anticoagulation, IS Immunosuppressants, ND No determined, PT Prothrombin time, T Thrombolysis.
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in BD [38,39]. Because venous inflammation is probably
the cause of deep vein thrombosis in patients with BD
[40], an immunosuppressive approach to management
seems reasonable, although no large randomized con-
trolled trials have directly addressed this issue. In a pre-
vious study on venous thrombosis in BD, we showed
that immunosuppressive agents significantly improved
the prognosis by decreasing the relapse of thrombosis by
four fold [8]. Another retrospective survey in 37 BD pa-
tients with venous thrombosis compared immunosup-
pressive, anticoagulation treatment and a combination of
immunosuppressants and anticoagulants [41]. Thrombosis
recurred in three of the four patients in the anticoagulanttreatment group (75%) compared to 2/16 cases (12.5%) in
the immunosuppressant group and to 1/17 cases (5.9%) in
the combination group.
The limitations of the present study due to the rarity
of both conditions must be kept in mind. This was a
retrospective analysis and we could not collect complete
longitudinal data in patients who were only seen inter-
mittently. Moreover, the studies in the literature are
mainly case-reports with a potential selection bias.
Nevertheless, this study indicates that (a) most BCS pa-
tients with BD present with IVC involvement and other
venous thrombosis and (b) TIPS are rarely used (c) des-
pite this, the overall outcome in patients with BD is not
different from that in patients with BCS without BD and
Desbois et al. Orphanet Journal of Rare Diseases  (2014) 9:104 Page 8 of 9(d) the association of immune suppression to anticoagu-
lation in medical therapy has a specific impact on BCS
in BD patients. Therefore, early combination immuno-
suppressants and anticoagulation therapy (with caval
recanalisation procedures when appropriate), appears to
be the treatment of choice in patients with BCS and BD.
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